ON THE THRESHOLD OF CHANGES IN THE TREATMENT OF STABLE CORONARY HEART DISEASE: FIRST RESULTS OF THE ISCHEMIA TRIAL
https://doi.org/10.21886/2712-8156-2020-1-1-38-42
Abstract
The goal of a large, prospective, randomized clinical trial, ISCHEMIA, was to evaluate a routine invasive treatment strategy compared to optimal drug therapy in patients with stable ischemic heart disease (IHD). At first glance, the question of the effect of coronary revascularization on the natural course of stable IHD received a definitive negative answer. However, excessive pessimism regarding coronary revascularization due to the results of the ISCHEMIA study is not justified and when interpreting the results of the project, it is necessary to take into account the criteria for exclusion of patients, conducting revascularization in some patients from the group of drug therapy. Meanwhile, already at present, a significant part of the resources used for widespread revascularization with stable IHD should be directed toward achieving the new goals of lipid-lowering therapy recommended by experts, the use of prognostically effective combined antithrombotic treatment and rational combinations of antianginal drugs.
About the Author
S. G. Kanorskii
Kuban State Medical University
Russian Federation
Russian Federation
Dr. Sci. (Med.), Prof.
Krasnodar
References
1. Patel K.K., Spertus J.A., Chan P.S., Sperry B.W., Thompson R.C., Al Badarin F. et al. Extent of myocardial ischemia on positron emission tomography and survival benefit with early revascularization. Journal of the American College of Cardiology. 2019;74(13):1645-1654. doi: 10.1016/j.jacc.2019.07.055.
2. Weintraub W.S., Hartigan P.M., Mancini G.B.J., Teo K.K., Maron D.J., Spertus J.A. et al. Effect of coronary anatomy and myocardial ischemia on long-term survival in patients with stable ischemic heart disease. Circulation. Cardiovascular quality and outcomes. 2019;12(2):e005079. doi: 10.1161/CIRCOUTCOMES.118.005079.
3. Knuuti J., Wijns W., Saraste A., Capodanno D., Barbato E., Funck-Brentano C. et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. European heart journal. 2020;41(3):407-477. doi: 10.1093/eurheartj/ehz425.
4. Maron D.J., Hochman J.S., Reynolds H.R., Bangalore S., O’Brien S.M., Boden W.E. et al. Initial Invasive or Conservative Strategy for Stable Coronary Disease. The New England journal of medicine. 2020;382(15):1395-1407. doi: 10.1056/NEJMoa1915922.
5. Bangalore S., Maron D.J., O’Brien S.M., Fleg J.L., Kretov E.I., Briguori C., et al. Management of Coronary Disease in Patients with Advanced Kidney Disease. The New England journal of medicine. 2020;382(17):1608-1618. doi: 10.1056/NEJMoa1915925.
6. Spertus J.A., Jones P.G., Maron D.J., Mark D.B., O’Brien S.M., Fleg J.L. et al. Health Status after Invasive or Conservative Care in Coronary and Advanced Kidney Disease. The New England journal of medicine. 2020;382(17):1619-1628. doi: 10.1056/NEJMoa1916374.
7. Boden W.E., O’Rourke R.A., Teo K.K., Hartigan P.M., Maron D.J., Kostuk W.J. et al. Optimal medical therapy with or without PCI for stable coronary disease. The New England journal of medicine. 2007;356(15):1503-1516. DOI: 10.1056/NEJMoa070829.
8. Sedlis S.P., Hartigan P.M., Teo K.K., Maron D.J., Spertus J.A., Mancini G.B. et al. Effect of PCI on Long-Term Survival in Patients with Stable Ischemic Heart Disease. The New England journal of medicine. 2015;373(20):1937-1946. doi: 10.1056/NEJMoa1505532.
9. Maron D.J., Mancini G.B.J., Hartigan P.M., Spertus J.A., Sedlis S.P., Kostuk W.J. et al. Healthy Behavior, Risk Factor Control, and Survival in the COURAGE Trial. Journal of the American College of Cardiology. 2018;72(19):2297-2305. doi: 10.1016/j.jacc.2018.08.2163.
10. Newman J.D., Alexander K.P., Gu X., O’Brien S.M., Boden W.E., Govindan S.C. et al. Baseline Predictors of Low-Density Lipoprotein Cholesterol and Systolic Blood Pressure Goal Attainment After 1 Year in the ISCHEMIA Trial. Circulation. Cardiovascular quality and outcomes.2019;12(11):e006002. doi: 10.1161/CIRCOUTCOMES.119.006002.
11. Al-Lamee R., Thompson D., Dehbi H.M., Sen S., Tang K., Davies J. et al. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. Lancet. 2018;391(10115):31-40. doi: 10.1016/S0140-6736(17)32714-9.
12. Borden W.B., Spertus J.A., Mushlin A.I., Roe M.T., McCoy L.A., Redberg R.F. Antianginal therapy before percutaneous coronary intervention. Circulation. Cardiovascular interventions. 2013;6(4):436-443. doi: 10.1161/CIRCINTERVENTIONS.112.000215.
13. Mach F., Baigent C., Catapano A.L., Koskinas K.C., Casula M., Badimon L. et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European heart journal. 2020;41(1):111-188. doi: 10.1093/eurheartj/ehz455.
Review
For citations:
Kanorskii S.G. ON THE THRESHOLD OF CHANGES IN THE TREATMENT OF STABLE CORONARY HEART DISEASE: FIRST RESULTS OF THE ISCHEMIA TRIAL. South Russian Journal of Therapeutic Practice. 2020;1(1):38-42. (In Russ.) https://doi.org/10.21886/2712-8156-2020-1-1-38-42
Views:
698
Email this article 